CoreRx, a contract formulator and manufacturer of complex pharmaceutical products, announced that the Company has completed a placement of Series A Preferred Stock with Signet Healthcare Partners.
Brian McMillan, V.P. of Formulations is a valuable asset to CoreRx. He brings many years of experience and talent and is a driving force in the success of CoreRx. With that aside, it's easy for any conversation with Brian to gravitate to his beloved "Buckeyes." It's very clear that Brian loves his roots. As an Ohio State University (OSU) alumni, he holds the school close to his heart. Based on an article posted in 2012, it's clear the feelings are mutual. CoreRx is honored to share an article posted by OSU where the spotlight is on Brian and his past and future accomplishments. We're happy to report that Brian did earn his M.S. in Pharmaceutical Chemistry from the University of Florida in 2013 and continues his relationship teaching at the University of South Florida, College of Pharmacy. We're fortunate at CoreRx to have such talented and skilled professionals among us.
Read the OSU article here: http://artsandsciences.osu.edu/alumni/experience/spotlights2012/mcmillan
Companies to Invest in New Facility, Increase Workforce
Tampa, FL (June 24, 2013) – The University of South Florida College of Pharmacy and CoreRx, Inc., a research-based drug development firm, received a $200,000 award from the Florida High Tech Corridor to bolster the training needed to prepare students for innovation and technology in the pharmaceutical industry.
Company to Invest Approximately $2 Million, Increase Workforce
CoreRx, Inc. is pleased to announce they are now occupying their new 35,000 square foot facility in Clearwater, FL. This distinct facility will enable CoreRx’s scientific staff to custom formulate, analyze and manufacture the highest quality pharmaceutical products for their client-partners.